more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead

Research Report
  ()
A full FDA clinical hold covers all studies of this hyperphagia candidate, and the company plans to unblind Phase 3 data. An analyst warned the trial "may need to be repeated in its entirety."
Tags: Biotechnology / Pharmaceuticals

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

  ()
PolyPid Ltd. (PYPD:NASDAQ) and Azurity Pharmaceuticals signed a deal worth up to US$330 million to commercialize D-PLEX100, an infection-prevention drug, in the U.S. and Canada.
Tags: Biotechnology / Pharmaceuticals

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

  ()
PolyPid enters a major commercialization deal with Azurity for D-PLEX100 targeting surgical site infections, with upfront payments and milestone potential supporting retail investors watching PYPD progress toward 2027 launch.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances VOXZOGO Toward Landmark US FDA Approval

  ()
BioMarin Pharmaceuticals Inc.'s (BMRN:NASDAQ) supplemental New Drug Application seeking traditional approval for VOXZOGO (vosoritide) to treat children with the genetic bone-growth disorder achondroplasia has been accepted.
Tags: Biotechnology / Pharmaceuticals

BioMarin Advances VOXZOGO Toward Full FDA Approval

  ()
BioMarin submits sNDA for traditional VOXZOGO approval in achondroplasia with a Feb 2027 PDUFA date backed by extensive long-term data and an expanding skeletal dysplasia market opportunity.
Tags: Biotechnology / Pharmaceuticals

Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

  ()
Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is selling its Phase 3 antibiotic to Biossil for up to US$104.5 million in milestones, refocusing on its oncology drug ivonescimab.
Tags: Biotechnology / Pharmaceuticals

Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target

  ()
Roth, Chardan Capital, and H.C. Wainwright have all issued "Buy" ratings on Coya Therapeutics Inc. (COYA:NASDAQ) in 2026. Read on to find out why analysts are intrigued.
Tags: Biotechnology / Pharmaceuticals

Houston ALS Biotech Coya Eyes 2028 Approval Path

  ()
Coya Therapeutics advances COYA 302 for ALS with strong analyst support and a key 2027 readout ahead. Discover the catalysts and industry trends driving this Houston biotech.
Tags: Biotechnology / Pharmaceuticals

Bullish Charts and Commercial Breakthroughs For Florida Biomanufacturer Could Fuel Upwards Valuation

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson takes a look at Dyadic International Inc. (DYAI:NASDAQ) as it secures strategic partnerships in the human and animal health, food technology, cell culture media, and industrial enzyme sectors.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Delivers Promising DMD Data With Fast Track Win

  ()
Satellos Bioscience reports strong six-month TRAILHEAD data for SAT-3247 in DMD adults, secures Fast Track status, and advances pediatric trials amid growing muscle disease market opportunity.
Tags: Biotechnology / Pharmaceuticals

Biotech With Muscle Disease Drug Uncovers Results in Trial Data

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) shares promising data from its study evaluating a drug to fight Duchenne muscular dystrophy. Find out why at least one expert says the study "delivered" great data.
Tags: Biotechnology / Pharmaceuticals

NASDAQ-Listed Duchenne Muscular Dystrophy Drugmaker Wins FDA Filing Acceptance Despite Confirmatory Trial Miss

Research Report
  ()
The FDA accepted the company's morpholino oligomer filings with a February 2027 PDUFA date, but a missed confirmatory trial endpoint clouds its path to full approval.
Tags: Biotechnology / Pharmaceuticals

Air Force Bases Renew Their Contracts With Cleantech Pioneer

  ()
Cleantech and life sciences innovator BioLargo Inc. (BLGO:OTCQX) says its engineering division has secured contract renewals worth over US$1.4 million. Find out why experts like this technology incubator's structure.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

BioLargo (BLGO) Aligns CEO Pay With Growth as Contracts Renew

  ()
BioLargo Inc. (BLGO) secures $1.4M Air Force contract renewals while advancing PFAS and wound care technologies through key partnerships and aligned leadership incentives.
Tags: Life Sciences Tools & DiagnosticsTechnologyBiotechnology / PharmaceuticalsSpecial Situations

How Do Analysts Rate This Biotech Focused on Chronic Inflammatory Diseases?

  ()
Find out what analysts think of clinical-stage biotech Abivax SA (ABVX:NASDAQ), which is focusing on harnessing the immune response in patients with chronic inflammatory diseases.
Tags: Biotechnology / Pharmaceuticals

Abivax SA (ABVX) UC Opportunity: Oral Therapy Catalyst

  ()
Abivax SA (ABVX) advances obefazimod through Phase 3 success in ulcerative colitis with NDA filing targeted for late 2026. Learn why this oral miR-124 therapy stands out for investors now.
Tags: Biotechnology / Pharmaceuticals

French Clinical-Stage Biotech's UC Drug Faces 'Best in Disease' Doubts as Analyst Lifts Target Ahead of 4Q26 FDA Filing

Research Report
  ()
A Wedbush analyst raised its target on a French biopharma's ulcerative colitis candidate but disputed bullish efficacy claims, flagging Jak competition and a 2027 Crohn's readout.
Tags: Biotechnology / Pharmaceuticals

Abivax SA (ABVX:NASDAQ) UC Data Fuels Biotech Opportunity

  ()
Abivax SA (ABVX:NASDAQ) reports strong obefazimod maintenance results in ulcerative colitis. Explore sector growth, analyst targets, catalysts, and what it means for investors.
Tags: Biotechnology / Pharmaceuticals

Drug Developer Scores Major FDA Nod, Eyes Big Gains in Muscle Disease Market

  ()
Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ) earns FDA Fast Track designation for its Duchenne treatment SAT-3247, positioning the company for potential breakthrough gains.
Tags: Biotechnology / Pharmaceuticals

Satellos Bioscience Fast Track Win Fuels DMD Hopes

  ()
Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne. Explore the market opportunity, clinical catalysts, analyst targets, and what retail investors should know now.
Tags: Biotechnology / Pharmaceuticals

Clinical-Stage Biotech Discloses Colitis Retreatment Results, Gets Mixed Ratings

  ()
Abivax SA (ABVX:NASDAQ) reports 69.7% clinical response and 45.0% remission rates in relapsed UC patients retreated with obefazimod in Phase 3 trial.
Tags: Biotechnology / Pharmaceuticals

Viking Therapeutics Expands Obesity Pipeline With VK3019 Phase 1

  ()
Viking Therapeutics launches Phase 1 trial for VK3019 amylin agonist. Discover how this dual-receptor candidate fits the company's expanding obesity strategy and upcoming catalysts for investors.
Tags: Biotechnology / Pharmaceuticals

uniQure Epilepsy Gene Therapy Data Draws Investor Focus

  ()
uniQure reports early AMT-260 results for refractory MTLE. See the trial data, pipeline catalysts, analyst price target, and what retail investors should watch next.
Tags: Biotechnology / Pharmaceuticals

A New Obesity Drug Just Reached Human Trials. Here's What Comes Next

  ()
Viking Therapeutics Inc. (VKTX:NASDAQ) initiated a Phase 1 clinical trial of its investigational weight-loss candidate VK3019, following FDA clearance of its IND application.
Tags: Biotechnology / Pharmaceuticals

San Diego Biopharma Begins First-in-Human Dosing of Obesity Drug as Phase 3 Catalysts Approach

Research Report
  ()
A San Diego clinical-stage biopharma dosed its first patient in a Phase 1 obesity study while advancing late-stage weight-loss programs toward key 20262027 readouts.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 107 Next